73results about How to "Promote gene expression" patented technology

An implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring is provided. A stimulation therapy lead includes helical electrodes configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins electrically connected to the helical electrodes. A neurostimulator includes an electrical receptacle into which the connector pins are securely and electrically coupled. The neurostimulator also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes in alternating cycles of stimuli application and stimuli inhibition that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials. Finally, the neurostimulator includes an integrated leadless heart rate sensor configured to sense heart rate and to record the sensed heart rate as data into a memory.

The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal.

An implantable device (11) for evaluating autonomic cardiovascular drive in a patient (10) suffering from chronic cardiac dysfunction is provided. A stimulation therapy lead (13) includes helical electrodes (14) configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins (28) electrically connected to the helical electrodes (14). A neurostimulator (12) includes an electrical receptacle (25) into which the connector pins (28) are securely and electrically coupled. The neurostimulator (12) also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes (14) in alternating cycles of stimuli application and stimuli inhibition (90) that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials. The neurostimulator (12) includes a recordable memory (29) storing a baseline heart rate. The neurostimulator (12) includes an integrated leadless heart rate sensor (31) configured to continually monitor heart rate in light of the baseline heart rate.

This present invention discloses nucleic acid compositions and methods that are useful for treating ischemic conditions in animals, particularly in mammals such as humans. Specifically, the invention discloses nucleic acid molecules comprising or encoding a sequence that modulates the stability of a transcript from a vascular endothelial growth factor gene, as well as pharmaceutical compositions containing such molecules, which arm useful for modulating angiogenesis or vascularization, especially in methods for treating ischemic conditions.

The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

The invention provides compositions and methods for increasing the secretion of mucus within the reproductive tract of a female mammal.

An implantable device (11) for evaluating autonomic cardiovascular drive in a patient (10) suffering from chronic cardiac dysfunction is provided. A stimulation therapy lead (13) includes helical electrodes (14) configured to conform to an outer diameter of a cervical vagus nerve sheath, and a set of connector pins (28) electrically connected to the helical electrodes (14). A neurostimulator (12) includes an electrical receptacle (25) into which the connector pins (28) are securely and electrically coupled. The neurostimulator (12) also includes a pulse generator configured to therapeutically stimulate the vagus nerve through the helical electrodes (14) in alternating cycles of stimuli application and stimuli inhibition (90) that are tuned to both efferently activate the heart's intrinsic nervous system and afferently activate the patient's central reflexes by triggering bi-directional action potentials. The neurostimulator (12) includes a recordable memory (29) storing a baseline heart rate.

Described are new methods for promoting the expression of apolipoprotein A1 (APO A1) for increasing levels of HDL, and assays for screening and identifying compounds for regulating expression of the APO A1 protein.

The invention discloses a tissue-engineered bone cartilage composite scaffold and a preparation method thereof, belonging to the technical field of biomaterials. The scaffold is of a multilayer integrated structure and comprises a cartilage tissue scaffold layer, a cartilage tissue calcified layer, a porous cell isolation membrane and a bone tissue scaffold layer. The cartilage tissue scaffold layer is inoculated with cartilage cells, and growth factors for promoting formation of cartilage are introduced to promote growth of cartilage cells. Main raw materials like heparan sulfate proteoglycan with good biocompatibility and degradability are selected and used and the method consisting of a cross-linking reaction, freeze drying, directional pore formation, compounding of multiple layers, overall integration and the like are carried out so as to obtain the functionalized multilayer integrated tissue-engineered bone cartilage composite scaffold with good mechanical properties. According to the invention, micro-nano hydroxyapatite crystal, degradable non-stoichiometric polyethylene glycol / poly(epsilon-caprolactone) nanometer coaxial short fiber, RGD-grafted heparan sulfate proteoglycan / oxidized sodium alginate and N-succinyl chitosan are compounded together to prepare the composite scaffold; and the composite scaffold is mainly used for restoration of full-thickness defects of articular cartilage and subchondral bone.

The present invention provides reconstituted histone octamers with multiple modifications (e.g. acetylation of all histones and trimethylation of histone H3K4) assembled onto plasmids for increased transcription post-transfection using our unique bi-lamellar invaginated liposomes (BIVs) to more effectively recruit the transcriptional machinery of human cancer cells post-transfection and substantially increase the production of therapeutic gene products.

The present invention relates to the field of biotechnology and particularly relates to a method for preparing a soybean Aglycin family peptide by using acetic acid. The method for preparing the soybean Aglycin family peptide by using acetic acid comprises the following steps: subjecting raw materials to cleaning, soaking, germination, grinding and extraction, separating the slag from the slurry through a ceramic membrane and an organic membrane, and subjecting obtained materials to freeze-drying. According to the technical scheme of the invention, the acetic acid is extracted from soybeans, and the ceramic membrane and the organic membrane are combined to use, wherein the pore size of the ceramic membrane is 0.1 [mu]m and the pore size of the organic membrane is 1500 D to 6000 D. In this way, small protein and polypeptide compounds, with the molecular weight thereof between 1500 D to 6000 D, are obtained. The method is simple in operation, thoroughly in extraction effect, easy in filtration, short in production cycle, greatly improved in yield and greatly reduced in production cost. Therefore, the industrial production is easily realized. A produced Aglycin product is in the form of light yellow powders, and is good in taste and high in purity. The Aglycin product can be used as functional food for the adjuvant therapy of type 2 diabetes for preventing diabetes.

The invention discloses recombinant pseudomonas putida, which is expressed on the basis of DNA integration. The invention also discloses a construction method for the recombinant pseudomonas putida, and the application of the recombinant pseudomonas putida in phosphorus removal from wastewater. The method of the invention is simple, and obtained genetically engineered bacteria have high-efficiency phosphorus removal capacity.

Genes are expressed by culturing cells comprising a host chromosome comprising an integrated artificial chromosome comprising recombinant genes, under conditions whereby each recombinant gene is expressed copy number dependently and position independently. Deletions increase expression from recombinant gene(s) inserted into the artificial chromosome.

The present invention relates generally to the treatment and prevention of diseases characterized by excess cell proliferation and / or activation. In particular, the present invention provides compositions and methods to suppress the activation and / or proliferation of various cells. In some preferred embodiments, the present invention provides compositions and methods to suppress the activation and / or proliferation of mesenchymally derived cells (including, but not limited to hepatic stellate cells), as well as cells with abnormal growth characteristics. In some particularly preferred embodiments, the present invention provides compositions and methods to inhibit or eliminate fibrosis. In alternative preferred embodiments, the present invention provides compositions and methods to induce fibrosis. In still further embodiments, the present invention provides methods and compositions to treat and / or prevent cancer.

The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP / PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP / PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke.

The invention discloses a loofah planting method. The loofah planting method comprises the following steps of (1) selecting and treating; (2) seedling seeding; (3) land arranging and fertilizer applying; (4) field planting; (5) harvesting. Loofah produced by the method has the advantages that the quality is high, the harvesting cycle is long, and the output is high. The method has the advantages that seeds are soaked into a seed treatment liquid, and are electrolyzed, so that the permeation property of seed coats is improved, cells in the seeds are promoted to suck water, and the quick maturing of incompletely matured seed embryos is promoted.

The present disclosure relates to microbial stem cell technology that enables a growing microbial culture to stably maintain two or more distinct cell types in a ratio that can be genetically programmed and / or dynamically controlled during cultivation. It is contemplated that embodiments described herein can be utilized to increase product yield in microbial fermentations and advanced engineering of biomaterials using genetically engineered microbial cells, among others.

The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal.

A vector having a region encoding a cold shock protein gene mRNA-origin 5′-nontranslated region, characterized in that the 5′-nontranslated region has a mutation having been transferred therein so as to change the distance of the stem structure formed by the region.

A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.

The invention provides a transcription factor PpNAC1 participating in synthesis regulation of peach ester aromatic substances, and belongs to the technical field of plant molecular biotechnology and genetic engineering. The nucleotide sequence of PpNAC1 is as shown in SEQ ID NO.1. In the invention, the transcription factor PpNAC1 can be combined with a promoter region (T / A) NN (C / T) (T / C / G) TNNNNNA (A / C) GN (A / C / T) (A / T) binding site and an ACGTA binding site of an acyltransferase PpAAT1 gene participating in synthesis of ester substances to activate expression of the PpAAT1 gene, thereby promoting synthesis of ester aromatic substances. It verifies that PpNAC1 expression keeps increasing as ripening of peach fruits. The expression mode of PpNAC1 is positively correlated with accumulationof volatile esters in fruits, and increasing of gene expression is prior to increasing of synthesis of esters.

The invention provides a regulator for improving intestine health of juvenile fish of micropterus salmoides at a feed change stage and a preparation method and application of the regulator and belongsto the technical field of feed additives. The regulator comprises 5-30% of tea polyphenol, 5-20% of oxidized konjac glucomannan, 20-50% of linseed oil, 10-30% of inulin and 25-40% of a carrier. The preparation method specifically comprises the following steps: putting the linseed oil into a stainless steel reaction kettle, slowly adding the carrier, performing uniform stirring so as to obtain a linseed oil mixture, screening the linseed oil mixture by using an 80-100-mesh sieve, respectively adding the tea polyphenol, the oxidized konjac glucomannan and the inulin, performing uniform mixing and stirring, inspecting contents of components of the obtained mixture, and performing bottling and packaging. The obtained regulator is used in preparation of feeds for the juvenile fish of the micropterus salmoides at the feed change stage, intestine health of the juvenile fish of the micropterus salmoides at the feed change stage can be greatly improved, intestinal diseases can be reduced, anduse of antibiotics in the breeding process can be reduced.

The invention provides a culture medium and a method for establishing and maintaining early embryonic-like cells of mammals. The culture medium is used for culturing pluripotent stem cells (PSC) of mammals, has definite chemical components, contains a basic culture medium for culturing stem cells, and is supplemented with an S-adenosylhomocysteine hydrolase (SAH) / polycomb inhibition complex (PRC) / EZH2 inhibitor and an HDAC inhibitor. By means of the culture medium, primate (human and non-human) animal PSC can be converted into pre-implantation internal cell mass-like cells (ICLC) or 8-cell embryonic-like cells (8CLC).

A vector having a region encoding a cold shock protein gene mRNA-origin 5′-nontranslated region, characterized in that the 5′-nontranslated region has a mutation having been transferred therein so as to change the distance of the stem structure formed by the region.

The invention belongs to the technical field of oral cavity health care, and particularly relates to a chewable composition (such as chewing gums) containing phosphosilicate glass and a preparation method of the chewable composition. The chewable composition containing phosphosilicate glass and a chewable substance are prepared, wherein after the phosphosilicate glass is in contact with oral cavity saliva, a series of chemical reactions can occur, and finally, the repairing effects of the phosphosilicate glass on the surfaces of teeth or gums can be exerted. In addition, the phosphosilicate glass in the chewable composition and the chewable substance has high dissolving-out properties and stable pH value, so that various gene expression can be promoted, and the purpose of preventing and treating oral cavity problems of oral cavity infection, oral cavity ulcer, gingivitis and the like can be achieved; and besides, through remineralization of the chewable composition on teeth, hemodia can be relieved. The preparation method disclosed by the invention is simple in technology, the raw materials are cheap and easy to obtain, and the chewable composition is suitable for industrialized mass production.

A recombinant adenovirus vector comprises eukaryotic cell promoter, operator, Kozak sequence, exogenous gene and PolyA signal sequence from 5′ to 3′ in the adenovirus vector backbone. Optionally, introns are inserted between the operator and Kozak sequence, and the exogenous gene is p53 gene. A recombinant adenovirus obtained by co-transfection of the adenovirus vector and adenovirus backbone is also included in the invention. Also disclosed are the preparation methods and uses of the recombinant adenovirus vector and the recombinant adenovirus, respectively. The present invention further discloses a pharmaceutical composition for treating cancers, which comprises the recombinant adenovirus.

The invention relates to a composition for improving cerebral neurotrophic function. The composition comprises, by weight, 91.1-99.8% of asparagus extract, 0-2.4% of phosphatidylserine, 0-2.4% of fungal extract, 0.09-1.6% of theanine and 0.09-2.0% of gamma-aminobutyric acid. The asparagus extract is solid powder or liquid, and refers to the extract, with asparagus saponin content not less than 0.3g / 100g, extracted from one or multiple of asparagus stems, leaves or leftovers; the fungal extract refers to the extract from one or multiple of shiitake mushroom, glossy ganoderma, hericium erinaceus, pleurotus cornucopiae and pleurotus eryngii; extraction solvents of the asparagus extract and the fungal extract both refer to water or mixture of ethyl alcohol and water. The composition can promote growth of the brain derived neurotrphic factor by increasing content of hippocampus acetyl choline, improve mechanisms such as neurotrophic growth factor gene expression, and play a role in improving the cerebral neurotrophic function.